ライフサイエンスコーパス: symptom onset

1 ng the endovascular procedure (within 7 h of symptom onset).

2 ally upset in the case period (1 hour before symptom onset).

3 that resolved completely within 24 hours of symptom onset.

4 pitalised cases admitted within </=4 days of symptom onset.

5 or Zika viremia is only about one week after symptom onset.

6 carriers on average 12 years before clinical symptom onset.

7 lisation, older age, and travelling prior to symptom onset.

8 ty and expense of acquiring data sets before symptom onset.

9 of patients survive more than 10 years from symptom onset.

10 usion (derivation cohort) with known time of symptom onset.

11 cal deficits who present within 4.5 hours of symptom onset.

12 all eligible patients within 4.5 h of stroke symptom onset.

13 dy-drug infusion within the first hour after symptom onset.

14 tion of phenotype can be achieved even after symptom onset.

15 ltivessel disease having PPCI within 12 h of symptom onset.

16 ptoms of dynein/dynactin diseases even after symptom onset.

17 nocompromised adults, died within 60 days of symptom onset.

18 e or placebo, beginning within 2 hours after symptom onset.

19 rculation were included up to 12 hours after symptom onset.

20 n-QW despite treatment within 12 hours after symptom onset.

21 rwent follow-up unenhanced CT 24 hours after symptom onset.

22 ng deficits presenting within 4.5 hours from symptom onset.

23 by trombolytic treapy within 3-6 hours after symptom onset.

24 treated intraarterially within 6 hours after symptom onset.

25 esity, is the better predictor of depressive symptom onset.

26 valescent plasma is administered early after symptom onset.

27 A28 mice when given either prior to or after symptom onset.

28 a was quantified between 2 and 13 days after symptom onset.

29 ajor cerebral artery occlusion beyond 3 h of symptom onset.

30 .5%) of patients presented within 2 weeks of symptom onset.

31 r first medical help later than 30 min after symptom onset.

32 lytic therapy is restricted to 3-4.5 h after symptom onset.

33 d 2 months and 6 months, respectively, after symptom onset.

34 defined as death that occurred within 1 h of symptom onset.

35 an ischemic stroke in the first 24 hours of symptom onset.

36 s were reperfused by primary PCI <12 h after symptom onset.

37 id diseases, and infectious illnesses before symptom onset.

38 tom onset and 396 (33%) 48 h or longer since symptom onset.

39 tutional symptom of influenza within 48 h of symptom onset.

40 diagnosed as having HL until 6 months after symptom onset.

41 d involvement of the fellow eye 1 year after symptom onset.

42 ecially when treatment is started soon after symptom onset.

43 nd stroke mimics (n = 20) within 24 hours of symptom onset.

44 demiology that rely on only a single test at symptom onset.

45 before development of TBM-IRIS through IRIS symptom onset.

46 ntion and presenting less than 12 hours from symptom onset.

47 favorably in patients presenting early after symptom onset.

48 s had IVT started within 4.5 hours of stroke symptom onset.

49 or endovascular therapy up to 18 hours after symptom onset.

50 l delay in the one individual treated before symptom onset.

51 to NCs, starting 11.2 years before expected symptom onset.

52 ells) or placebo between 24 h and 48 h after symptom onset.

53 for days 2-90, given orally) within 24 h of symptom onset.

54 ATXN1 mRNA by rAAV.miS1 when delivered after symptom onset.

55 iverge already at 17.8 years before expected symptom onset.

56 by stroke specialists within 24 hours after symptom onset.

57 everse disease readouts when delivered after symptom onset.

58 rapeutic disease-modifying time window after symptom onset.

59 ated with increased WMH well before expected symptom onset.

60 crease approximately 6 years before expected symptom onset.

61 controls, more than 15 years before expected symptom onset.

62 rresponds to the second and third week after symptom onset.

63 euroimaging scanning within a fortnight from symptoms onset.

64 patients were enrolled within 12 hours from symptoms onset.

65 Children with SAFS had earlier symptom onset (0.5 vs 1.5 years, P = .006), higher total

66 2), those randomised more than 300 min after symptom onset (1.76, 1.05-2.97), and those not eligible

67 fter endovascular therapy (median time after symptom onset, 12 hours) and at day 5 were identified.

68 condition) presenting to care </=2 days from symptom onset, 195 (19%) were prescribed an antiviral me

69 Patients presenting within 4 weeks of symptom onset (30 with diabetes mellitus, 62 control pat

70 as started within a median of 285 minutes of symptom onset; 51 (41%) patients achieved a mTICI 2b, an

71 hain reaction negativity was 46.4 days after symptom onset (95% confidence interval, 11-82.6).

72 ed with treatment initiated within 2 days of symptom onset (adjusted hazard ratio [HR 1.23] [95% CI 1

73 eceived medical help later than 30 min after symptom onset, adrenaline auto-injector prescription is

74 criteria, exclusion of concerning features (symptom onset after age 50 years, unexplained weight los

75 t (EYO) by subtracting the affected parent's symptom onset age from the participant's age.

76 Median symptom onset age was 44 years (range = 8-103), and 54%

77 ly complete penetrance and a distinct age of symptom onset, allows investigation of presymptomatic pa

78 sk of becoming overweight or obese, and PTSD symptom onset alters BMI trajectories over time.

79 89; and BMI trajectory before and after PTSD symptom onset among women who developed PTSD symptoms in

80 , 835 (30%) presented to care </=2 days from symptom onset; among those, 126 (15%) were prescribed an

81 ere enrolled: 794 (67%) less than 48 h since symptom onset and 396 (33%) 48 h or longer since symptom

82 ence was estimated to be 79% one month after symptom onset and 64% after 400 days.

83 ample mean (SD) age was 64.1 (10.3) years at symptom onset and 67.9 (9.9) years at Three Words Three

84 ts with acute first stroke (within 5 days of symptom onset and 72 h of hospital admission).

85 acute ischemic stroke within 4.5 hours from symptom onset and a baseline National Institutes of Heal

86 d to determine if clinician-estimated age of symptom onset and age at diagnosis of bvFTD differed bet

87 for sex, the TBI+ bvFTD group had an age of symptom onset and age of diagnosis that was on average 2

88 uded in the study; patients were assessed at symptom onset and at months 4, 8, 12, 18, and 24, by use

89 roups according to the time interval between symptom onset and CABG: group A, <24 hours (133 patients

90 Time since symptom onset and clinical outcome were used as independ

91 ll, 252 women with PMDD started treatment at symptom onset and continued until the first few days of

92 y (TBI) is associated with an earlier age of symptom onset and diagnosis in a large sample of patient

93 agnosis is associated with an earlier age of symptom onset and diagnosis in patients with bvFTD.

94 ose with a delay of less than 1 year between symptom onset and diagnosis.

95 mportance of both reducing the delay between symptom onset and hospitalisation and rapid national and

96 neurofilament-heavy chain) are normal before symptom onset and increased by at least an order of magn

97 nal analysis at baseline showed that earlier symptom onset and longer duration since onset was associ

98 erwent perfusion CT within 6 hours of stroke symptom onset and magnetic resonance (MR) imaging at 24

99 nonsurvivors at very early time points after symptom onset and may be predicative of outcome.

100 SCA17 mice experienced earlier neurological symptom onset and more severe Purkinje cell degeneration

101 on of gamma-MNs in SOD1(G93A) mutants delays symptom onset and prolongs lifespan, demonstrating a pat

102 ants in >1 gene, which influenced the age of symptom onset and supports oligogenic inheritance as rel

103 f-administration could reduce delays between symptom onset and treatment, and attack burden.

104 Also, to determine whether age at PTSD symptom onset and type of trauma influence the PTSD-food

105 ion patients presenting within 3 hours after symptom onset and unable to undergo pPCI within 1 hour.

106 myocardial infarction presenting early after symptom onset and undergoing primary percutaneous corona

107 995 patients who arrived within 4.5 hours of symptom onset and were treated with IV rtPA, 7621 (22.4%

108 ary intervention (PCI) within 12 hours after symptom onset and who had complete occlusion of the culp

109 Tuberculosis symptom-onset and diagnosis dates were recorded for 852

110 oms onset or shortening the duration between symptoms onset and isolation may lead to more Ebola infe

111 patients with acute NAION (within 14 days of symptom onset) and 15 control patients with age-related

112 a expansion, all occurring within 48 h after symptom onset) and five (19%) of 27 in the PCC group (no

113 itamin D deficiency, tuberculosis infection, symptom onset, and diagnosis may explain the enigmatic l

114 In this retrospective study, we examined symptom onset, and genetic and neuropathological data fr

115 ed subgroups stratified by age, sex, time of symptom onset, and known ischemic heart disease.

116 relationships of baseline Q waves, time from symptom onset, and reperfusion strategy with in-hospital

117 The patient died 22 years after symptom onset, and the final diagnosis was confirmed at

118 s disease can be predicted many years before symptom onset, and thus makes an ideal model for studyin

119 om type and duration, the event resulting in symptom onset, and whether the player sought medical att

120 wn neuroimaging and cognitive changes before symptoms onset, and we aimed to identify whether such ch

121 Identification of incident cases, symptom onset, antimicrobial treatment, immunization rea

122 tures, investigated associations with age at symptom onset, APOE genotype, and mutation position, and

123 rombolytic treatment more than 3 hours after symptom onset appear favorable.

124 atus defined by days between vaccination and symptom onset as the predictor.

125 cteristics between cohorts, including age at symptom onset, associated symptoms and signs, rates of p

126 re were no cases of Ebola virus disease with symptom onset at least 10 days after randomisation, wher

127 Viruses were delivered prior to or after symptom onset at multiple doses.

128 during follow-up among women reporting PTSD symptom onset before 1989; and BMI trajectory before and

129 Two participants (4%) experienced symptom onset before receipt of the vaccines.

130 with 2 reported incidents of pertussis with symptom onset between 1 January 2010 and 31 December 201

131 California Department of Public Health with symptom onset between June 2012 and July 2015.

132 ion patients presenting within 3 hours after symptom onset but unable to undergo pPCI within 1 hour.

133 Still, treatment following symptom onset can be effective; Glut1 repletion in early

134 ng data were reviewed: age, sex, laterality, symptom onset, clinical presentation, histopathology, tr

135 ation carriers near their anticipated age of symptom onset compared with asymptomatic mutation noncar

136 was beneficial at 4.5 hours or earlier after symptom onset compared with the natural history group (1

137 mivir who were enrolled less than 48 h since symptom onset compared with those given placebo, but thi

138 <120 days), county of residence, and closest symptom onset date with 1-4 nonfatal hospitalized cases.

139 Symptom onset dates ranged from April 2010 to January 20

140 uding site of onset (bulbar or limb), age at symptom onset, delay from onset to diagnosis and the use

141 predominantly motor involvement, aggressive symptom onset, early axonal involvement, and poor respon

142 Fourteen days after symptom onset, elevated levels of antibodies to A(H7N9)

143 focal dystonia evaluated within 5 years from symptom onset, enrolled in the Natural History Project o

144 calculated the estimated years from expected symptom onset (EYO) by subtracting the affected parent's

145 c memory as a function of estimated years to symptom onset (EYO) were analyzed.

146 below 1% when treatment was initiated after symptom onset for twice-a-day intakes.

147 ted with intravenous tPA within 4.5 hours of symptom onset from 888 surveyed hospitals between June 2

148 onance at 1.5 T seven days (5-10 days) after symptom onset (FU0), after 5 weeks (FU1), and after 6 mo

149 ICP at 9-15 weeks of gestation and prior to symptom onset (group 1 cases/samples: ICP n = 35/80, unc

150 onset < 34 weeks) and late-onset PE (LO-PE; symptom onset > 34 weeks) cohorts.

151 006 to 2012 of laboratory-confirmed PML with symptom onset >/=30 days following NTZ withdrawal.

152 Delivery of scAAV9-SMN after symptom onset had a marked impact on phenotype, electrop

153 als in critical condition within 4 days from symptom onset has a high chance of eliminating the disea

154 iv) orthostatic intolerance within 1 year of symptom onset (hazard ratio 1.28, P < 0.014); (v) older

155 i) urinary catheterization within 3 years of symptom onset (hazard ratio 1.67, P < 0.003); (iv) ortho

156 associated with less years before estimated symptom onset, higher global Abeta brain burden, and wit

157 ically from noncarriers by an earlier age at symptom onset, higher prevalence of a positive family hi

158 of supratentorial intracerebral haemorrhage symptom onset if they had used antiplatelet therapy for

159 ithin 12 hours and again at 48+/-24 hours of symptom onset in 172 patients with imaging-confirmed AIS

160 Conversion occurred after 2 years of symptom onset in 30% of patients.

161 ptomatic from asymptomatic subjects prior to symptom onset in challenge studies.

162 d by at least an order of magnitude at early symptom onset in CSF (pNF-H) or serum and CSF (NF-L).

163 estimating R for the case with the earliest symptom onset in each cluster (Rindex).

164 initiated an average of 2.6 months following symptom onset in Group 1 and 2.5 months in Group 2.

165 ll in samples obtained 13 days or more after symptom onset in index patients.

166 STEMI patients presenting <12 h from symptom onset in Killip class I to II without atrioventr

167 lination and neurodegeneration often precede symptom onset in multiple sclerosis (MS).

168 n activator, given between 3 h and 9 h after symptom onset in patients with occlusion or high-grade s

169 We found that symptom onset in R6/2 and Q175 HD mouse models was not a

170 whom treatment was started within 5 days of symptom onset, in an urban setting in Bangladesh.

171 d those seen with acute administration after symptom onset, including partial reversal of striatal de

172 pinal cord compared with control mice before symptom onset, indicating a possible mechanistic role in

173 alysed genotypic and phenotypic data (age at symptom onset, initial cognitive or behavioural symptoms

174 cation, head CT performed within 72 hours of symptom onset, initial DS angiographic results negative

175 se of a stent retriever within 6 hours after symptom onset (intervention group).

176 Loss of consciousness at symptom onset is an important manifestation of early bra

177 Widespread neuropathology prior to symptom onset is consistent with patient studies, wherea

178 les well-informed prospective studies, since symptom onset is near certain and age of onset is predic

179 intravenous thrombolysis because the time of symptom onset is unknown.

180 tPA, particularly into the first hour after symptom onset, leading to substantially better outcomes.

181 between the individual's dates of birth and symptom onset ('lifetime'), or to that between 1980 and

182 Younger age at symptom onset, longer delay from onset to diagnosis and

183 tures associated with early-onset PE (EO-PE; symptom onset < 34 weeks) and late-onset PE (LO-PE; symp

184 domly assigned patients (1:1:1 stratified by symptom onset </=4 days or 5-6 days) to receive 300 mg o

185 infarct location (anterior/nonanterior) and symptom onset (</= 3 h or >3 h).

186 </=II anterior STEMI presenting early after symptom onset (<6 h) and randomized them to pre-reperfus

187 s, the GBA mutation carriers were younger at symptom onset (mean [SD] age, 65.7 [11.7] vs 72.1 [5.1]

188 d carriers of these variants were younger at symptom onset (mean [SD] age, 67.4 [8.5] vs 71.3 [8.9] y

189 In the week following symptom onset, mean viremia remained stable, and the CFR

190 for the insula (at 10 years before expected symptom onset, mean volume as a percentage of total intr

191 e temporal lobe (at 10 years before expected symptom onset, mean volume as a percentage of total intr

192 X levels were associated with earlier age of symptom onset (median ePPIX levels for those who develop

193 Patients with CS were older at the age of symptom onset, more likely to have comorbidities, and de

194 Among patients treated within 3 hours of symptom onset, mortality was 12.5% (95% CI confidence in

195 ong patients treated more than 3 hours after symptom onset, mortality was 2.9% (95% CI confidence int

196 and individuals with LOAD concerning age at symptom onset (mutation carriers: mean, 75 years [range,

197 Symptom onset occurred at 10.8 (interquartile range, 6.8

198 more strongly related to food addiction when symptom onset occurred at an earlier age.

199 ious disease represents the duration between symptom onset of a primary case and symptom onset of its

200 ss starts one to two decades before expected symptom onset of ADAD.

201 n activator (rtPA) within 4(1/2) hours after symptom onset of ischemic stroke, 128 (3.3%) had sICH.

202 between symptom onset of a primary case and symptom onset of its secondary cases.

203 predict progression from normal cognition to symptom onset of mild cognitive impairment or dementia:

204 al dystonia patients had a history, prior to symptom onset, of significantly more frequent episodes o

205 Prior to motor symptom onset or neuronal cell loss in HD, levels of the

206 her endovascular thrombectomy within 12 h of symptom onset or standard care (control), with a primary

207 h desmoteplase (90 mug/kg) given 3-9 h after symptom onset or to placebo.

208 Serum and urine collected within 4 weeks of symptom onset or within 6 weeks of travel were tested wi

209 ion of latent individuals diagnosed prior to symptoms onset or shortening the duration between sympto

210 1.5-27.8) and those treated > 6 hours after symptom onset (OR = 13.7, 95% CI = 1.4-140).

211 When initiated within 24 hours of symptom onset, oral zinc is associated with a shorter du

212 clinical trials as even after 16.8 years of symptom onset, over half of JDM patients still have acti

213 , there was a midsummer peak in tuberculosis symptom onset (P < .05) followed after 3 weeks by a late

214 83.9 to 89.3%) during the first 14 days post-symptom onset (p.s.o.).

215 forming of electrophysiology </=7 days after symptom onset (p=0.045), indicating their greater useful

216 helps detect earlier (5.2 vs 2.3 days before symptom onset, P = .004) and more (3.1 vs 0.3, P = .008)

217 erlay in clinical presentation, older age of symptom onset, presence of cardiovascular comorbidities,

218 Timing of symptom onset, presentation to hospital, first neuroimag

219 Symptom onset ranged from 1 to 8 days, with peak onset 3

220 bitor of extracellular PPIA, MM218, given at symptom onset, rescued motor neurons and extended surviv

221 oss of lean mass, and their inhibition after symptom onset reverses anorexia.

222 ndings support clinical anecdotes of CNS ADS symptom onset shortly after vaccination but do not sugge

223 nance imaging performed 90 days or less from symptom onset, spinal cord T2-hyperintense lesion less t

224 ke who could be treated within 8 hours after symptom onset, stent retriever thrombectomy reduced the

225 ismatch profile treated up to 18 hours after symptom onset supports a randomized trial of endovascula

226 peak viremia levels at an earlier time after symptom onset than nonsurvivors (day 5 versus day 7) and

227 sminogen activator (tPA) within 4.5 hours of symptom onset, the most evidence-based effective emergen

228 large ST-segment elevation MI within 6 h of symptom onset, Thrombolysis In Myocardial Infarction (TI

229 atment can be shortened to the interval from symptom onset through the beginning of menses.

230 Median time from symptom onset to arterial puncture was 227 minutes (inte

231 Among the endovascular group, symptom onset to arterial puncture was 238 minutes (IQR,

232 ascular group declined with longer time from symptom onset to arterial puncture: cOR at 3 hours, 2.79

233 P=0.01, and 9 minutes, P<0.01, respectively; symptom onset to balloon inflation: 31.5 minutes for wom

234 patients (43%) died, with a median time from symptom onset to death of 8 days (interquartile range, 7

235 onic progression with a median duration from symptom onset to death or last visit of 5 years (range 2

236 Median disease duration from symptom onset to death was 7.51 years (95% confidence in

237 Shorter disease duration from cognitive symptom onset to death was observed in men (beta, -0.73;

238 The median time from symptom onset to diagnostic neuroimaging was 24.3 h in A

239 Stroke Scale [NIHSS] = 16, median time from symptom onset to endovascular therapy = 5.2 hours).

240 Time from symptom onset to first antegrade flow was 180 +/- 67 min

241 Among these 22 children, median time from symptom onset to first CT was 2 hours (interquartile ran

242 s differed from self-transported patients in symptom onset to first medical contact time (median, 47

243 significant difference in the duration from symptom onset to groin puncture (254 minutes for the IVT

244 y arrived at a referring facility had longer symptom onset to groin puncture times compared with pati

245 The time from symptom onset to initiation of therapy in survivors did

246 Mean (SD) total delay from symptom onset to initiation of treatment was 407 (665) d

247 Median duration from symptom onset to last follow-up was 25 (range, 2-223) mo

248 no between-group difference in the time from symptom onset to metoprolol bolus.

249 lasminogen activator (tPA) within 3 hours of symptom onset to more recent guideline-recommended use u

250 The median time from symptom onset to nasal swab was 2 days; 65.4% of samples

251 versus 10.0%), consistent across times from symptom onset to presentation (15.4% versus 9.9% </=3 ho

252 g and exclusion of patients with >6 hours of symptom onset to protect.

253 5 years [SD, 13.1]; women, 47.0%), time from symptom onset to randomization was 196 minutes (IQR, 142

254 Mean times from symptom onset to randomization were 129 +/- 56 min in pa

255 d and randomly assigned (1:1) within 12 h of symptom onset to receive routine manual thrombectomy wit

256 Mean time from symptom onset to reperfusion (ie, procedure end) was 325

257 The relation between time from (a) symptom onset to reperfusion and (b) imaging to reperfus

258 lts In the stent retriever arm of the study, symptom onset to reperfusion time of 150 minutes led to

259 ncture was 238 minutes (IQR, 180 to 302) and symptom onset to reperfusion was 286 minutes (IQR, 215 t

260 Median time from symptom onset to rituximab initiation was 414 days (rang

261 ts are likely to be highest if the time from symptom onset to treatment is within 60 minutes, termed

262 mpared with patients with a longer time from symptom onset to treatment, patients who received golden

263 s who might benefit despite long delays from symptom onset to treatment, the proportion of patients w

264 aseline thrombocytosis, multivessel disease, symptom onset-to-balloon time, and total stent length.

265 Symptom onset-to-imaging time was not associated with ou

266 Despite the fact that symptom onset typically occurs during early childhood, f

267 ubacute stroke (3-14 days after neurological symptom onset) underwent MRI examination.

268 ker trajectories across estimated years from symptom onset using linear mixed models, and compared th

269 For the RP patients, the median age at symptom onset was 4.0 years.

270 Patients' mean (SD) age at symptom onset was 4.4 (4.4) years.

271 Median age at neurologic symptom onset was 42 years (range, 21-73 years); there w

272 Symptom onset was 9-20 days after treatment initiation,

273 Median survival from symptom onset was 9.8 years (95% CI 8.8-10.7) and median

274 The median duration between exposure and symptom onset was approximately 1 day.

275 but neither histopathology nor the speed of symptom onset was associated with a poor prognosis.

276 At baseline, older age of symptom onset was associated with better VA, and a longe

277 HBAT administration within 2 days of symptom onset was associated with shorter hospital and i

278 ymptoms (>40 years); the mean age for asthma symptoms onset was 30.2 years and for asthma diagnosis 3

279 treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortal

280 Age, sex, and approximate time of symptom onset were also recorded for each patient.

281 Pulmonary function tests and time since symptom onset were collected retrospectively from the el

282 is who enrolled in the ONTT within 8 days of symptom onset were included in analyses.

283 n the anterior circulation within 6 hours of symptom onset were included.

284 olumes at baseline and within 48 hours after symptom onset were measured in 418 patients with spontan

285 of 707 patients referred for STEMI <12 h of symptom onset were randomized in 4 high-volume radial ce

286 tion myocardial infarction within 6 hours of symptom onset were randomized to peritoneal hypothermia

287 ic stroke who could be treated within 8 h of symptom onset were randomly assigned to medical therapy

288 eous coronary intervention within 6 hours of symptoms onset were randomized to receive intravenous me

289 Professional exposure and short latency of symptoms onset were risk factors for a positive result i

290 later intervention (<3 versus >3 months from symptom onset) were associated with CA3 atrophy.

291 had CT angiography within 6 and 12 hours of symptom onset, were categorized according to the occlusi

292 CSF neurofilaments were increased before symptom onset, while prion seeding assay was negative.

293 mong the 16 million persons at prime age for symptom onset who had served in the military in World Wa

294 ntiating between ICH and IS within 4.5hrs of symptom onset with a sensitivity of 61% and a specificit

295 with VKA-ICH who presented within 12 h after symptom onset with an INR of at least 2.0 were randomly

296 or less) when treated within 4.5 hours after symptom onset with intravenous recombinant tissue plasmi

297 OR, 1.02 per 1-year increased age; P<.0001), symptom onset within 24 hours of admission (aOR, 1.80; P

298 water uptake identifies stroke patients with symptom onset within 4.5 hours with high accuracy and ma

299 and further characterise subtypes by time of symptom onset within pregnancy and three post-partum per

300 After PTSD symptom onset, women with at least 4 symptoms had a fast